Article: Autologous formalin-fixed tumor vaccine suppressed re-recurrence of HCV-related hepatocellular carcinoma following 29 unsuccessful treatments with extensive conventional therapy: a case report

Treatment of hepatocellular carcinoma (HCC) with autologous formalin-fixed tumor vaccine after primary resection has been shown to suppress the recurrence of hepatitis B virus-associated HCC, but the effect of this treatment on hepatitis C virus (HCV)-related disease has not yet been clarified. Here, we report a case of a patient with repeat recurrent HCC that was associated with HCV who had endured 29 episodes of HCC recurrence despite a variety of therapy using conventional methods. Finally, treatment with a single course of autologous formalin-fixed tumor vaccine resulted in suppression of potential further re-recurrence of HCC for more than 43 months without any additional treatment.

Citing Articles

Successful monotherapy with autologous formalin-fixed tumor vaccine for a Stage IV uterine cancer patient who rejected rational chemotherapy and immune checkpoint inhibitor treatment.

Fukuda K, Ohno T Clin Case Rep. 2023; 11(6):e7513.

PMID: 37305860 PMC: 10250682. DOI: 10.1002/ccr3.7513.

Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine.

Kuranishi F, Imaoka Y, Sumi Y, Uemae Y, Yasuda-Kurihara H, Ishihara T Int J Breast Cancer. 2018; 2018:4879406.

PMID: 29576883 PMC: 5822812. DOI: 10.1155/2018/4879406.

Complete remission of chemo-refractory multiple-metastatic upper tract urothelial carcinoma by autologous formalin-fixed tumor vaccine.

Miyoshi T, Kashiwabara T, Asahi A, Kataoka T, Maruyama T, Okada R Clin Case Rep. 2017; 5(11):1780-1784.

PMID: 29152270 PMC: 5676256. DOI: 10.1002/ccr3.1179.

A transient increase and subsequent sharp decrease of chemo-refractory liver-metastasized uterine cervical small cell carcinoma to autologous formalin-fixed tumor vaccine plus anti-PD-1 antibody.

Miyoshi T, Kataoka T, Asahi A, Maruyama T, Okada R, Uemae Y Clin Case Rep. 2016; 4(7):687-91.

PMID: 27386130 PMC: 4929807. DOI: 10.1002/ccr3.596.

Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3.

Kawashima I, Kawashima Y, Matsuoka Y, Fujise K, Sakai H, Takahashi M Clin Case Rep. 2015; 3(6):444-7.

PMID: 26185646 PMC: 4498860. DOI: 10.1002/ccr3.279.

References

1.

Kuang M, Peng B, Lu M, Liang L, Huang J, He Q . Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004; 10(5):1574-9. DOI: 10.1158/1078-0432.ccr-03-0071. View

2.

Nagano H, Monden M . [FAIT (FU arterial infusion and interferon therapy) for hepatocellular carcinoma]. Nihon Rinsho. 2006; 64(7):1314-8. View

3.

Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S, Takeda Y . Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer. 2007; 110(11):2493-501. DOI: 10.1002/cncr.23033. View

4.

Ishikawa E, Tsuboi K, Yamamoto T, Muroi A, Takano S, Enomoto T . Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci. 2007; 98(8):1226-33. PMC: 11158799. DOI: 10.1111/j.1349-7006.2007.00518.x. View

5.

Ikeda K, Kobayashi M, Saitoh S, Someya T, Hosaka T, Akuta N . Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients. Oncology. 2003; 65(3):204-10. DOI: 10.1159/000074472. View

Autologous Formalin-fixed Tumor Vaccine Suppressed Re-recurrence of HCV-related Hepatocellular Carcinoma Following 29 Unsuccessful Treatments with Extensive Conventional Therapy: a Case Report